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ABSTRACT  40 
New data from the Danish National Fungaemia Surveillance 2012-15 is reported and 41 
epidemiological trends are investigated in a 12-year perspective (2004-15). During 2012-15, 1900 42 
out of 1939 (98%) fungal bloodstream isolates were included. The average incidence was 43 
8.4/100,000 inhabitants and this appears to be stabilizing after the increase to 10.1/100,000 in 44 
2011. The incidence was higher in males than females (10.0 vs 6.8) and in patients above 50 years, 45 
mainly driven by an increasing incidence among 80-89 years old males (65.3/100,000 in 2014-15). 46 
The proportion of Candida albicans decreased 2004-15 (64.4% to 42.4%) in parallel with a 47 
doubling of Candida glabrata (16.5% to 34.6%, p<0.0001). C. glabrata was more common among 48 
females (34.0% vs. 30.4% in males). Following an increase in 2004-11 the annual drug use 49 
stabilised during the last 2-3 years but remained higher than in other Nordic countries. This was 50 
particularly true for the fluconazole and itraconazole use in the primary healthcare sector which 51 
exceeded the combined national use of these compounds in each of the other Nordic countries. 52 
Fluconazole susceptibility decreased (68.5%, 65.2% and 60.6% in 2004-7, 2008-11 and 2012-15, 53 
respectively, p<0.0001) and echinocandin resistance in Candida emerged (0%, 0.6% and 1.7%, 54 
respectively, p<0.001). Amphotericin B susceptibility remained high (98.7%). Among 16 (2.7%) 55 
echinocandin-resistant C. glabrata isolates (2012-15), 13 harboured FKS mutations and five (31%) 56 
were multidrug resistant. 57 
The epidemiological changes and the increased incidence of intrinsic and acquired resistance 58 
emphasise the importance of continued surveillance and of strengthened focus on antifungal 59 
stewardship.60 
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INTRODUCTION 61 
Candidaemia remains a threat to susceptible patients and continues to carry a high crude 30-days 62 
mortality of 30-40% (1–3). The mortality is linked to infecting species, co-morbidity, underlying 63 
disease, age, and time to initiation of appropriate treatment (3, 4). However, as diagnosis of 64 
invasive candidiasis is often delayed, diligent attention to intravascular devices are important and 65 
empiric treatment recommendations must be founded on reliable contemporary epidemiology (5). 66 
Institutional studies are affected by referral practices and departments served. In general, 67 
population-based studies are less prone to bias, especially when the study base becomes large and 68 
representative for entire countries. Nationwide surveillance data is available from Australia, 69 
Scotland, Finland, Iceland, Norway, Sweden, and Denmark (6–18). In Denmark, an increasing 70 
candidaemia incidence was demonstrated during 8 years reaching 10.1/100,000 inhabitants in 71 
2011 (18). Although increasing incidence rates have also been found elsewhere, the Danish 72 
incidence is notably high compared to other reported contemporary nationwide incidence rates of 73 
2.4-5.7/100.000 inhabitants (12–16). 74 
Besides increasing incidence rates another common observation is the changing species 75 
distribution to non-albicans species and particularly C. glabrata in the northern hemisphere, 76 
Australia and Taiwan and C. parapsilosis in southern Europe and South America (3, 12, 13, 19, 20)) 77 
at the expense of C. albicans. The increase in C. glabrata has been coupled with an increased use 78 
of azoles for which C. glabrata is intrinsically less susceptible (18, 21, 22).  79 
From 2001 the echinocandins were introduced in Europe and the USA and in 2009-12 80 
incorporated into candidaemia management guidelines as the first-line treatment (23–27). 81 
Following the increased use, reports of acquired resistance has emerged among several different 82 
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species but especially C. glabrata (28–31), thereby warranting continued surveillance and 83 
monitoring. The aim of this population based nationwide study was to update and assess 84 
incidence and susceptibility patterns of fungaemia in Denmark during a 12-year period.85 
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MATERIAL AND METHODS 86 
Population and surveillance 2012-15 87 
Incidences per 100,000 inhabitants were calculated using the population by January 1st each year 88 
(www.statistikbanken.dk). The Danish population increased 1.4% from 5,580,516 to 5,659,715 89 
inhabitants from 2012-15. The mean was used for incidence rates calculated for periods of >1 90 
year. National annual number of admissions and bed days were available from The Danish Health 91 
Data Authority at www.eSundhed.dk. The local study representative reported population, 92 
numbers of admissions and bed days for hospitals within geographical capture area serviced by 93 
each centre of clinical microbiology. All Danish residents have access to universal tax-supported 94 
free-of-charge healthcare. All centres of clinical microbiology have specific geographic capture 95 
areas as specified previously (18), however, due to public health reforms the number was reduced 96 
from 13 to 11 (as centres 3 and 4 were administratively merged in 2012 (geographically separated 97 
blood culturing sites remained) and centres 12 and 13 fully merged in 2013). Original numbering 98 
of centres was retained to allow direct comparison with previous reports (17, 18).  99 
Isolates were referred to the National Reference Mycology Laboratory for species verification and 100 
susceptibility testing (see below). Completeness was ensured through comparison with local 101 
electronic laboratory records. A total of 39 out of 1939 (2.0%) isolates were not referred and 102 
therefore excluded from the susceptibility paragraphs (14 C. albicans, 14 C. glabrata, 2 C. 103 
tropicalis, 2 C. parapsilosis, 1 each of C. krusei, C. lusitaniae and C pellliculosa, and 2 unidentified 104 
Candida species).   105 
Two blood culture (BC) systems were used: BACT/ALERT (bioMérieux, Marcy l’Etoile, France) and 106 
BACTEC (Becton Dickinson, Franklin Lakes, NJ, USA), accounting for the detection of 77.9% and 107 
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22.1% of cases, respectively. For fungaemia patients with successive fungal bloodstream infections 108 
over time, subsequent episodes were included if they occurred at least 21 days apart or were 109 
caused by a different species consistent with previous reports (17, 18, 32). 110 
Species identification 111 
Identification was performed as previously described including matrix- assisted laser 112 
desorption/ionization time-of-flight mass spectrometry (Bruker, Bremen, Germany) (18) with the 113 
addition of DNA sequencing as described below. 114 
Susceptibility testing 115 
Susceptibility testing was done contemporaneously for the referred isolates and included 116 
amphotericin B, voriconazole and isavuconazole (98.0% of the isolates), anidulafungin and 117 
micafungin (97.9% of the isolates), and fluconazole (97.6% of isolates) according to the EUCAST 118 
definitive document E.Def 7.3 (33). Exceptions were amphotericin B (prior to January 2015) for 119 
which E-test (bioMérieux, Herlev, Denmark) and RPMI-1640 2% glucose agar buffered with MOPS 120 
(SSI Diagnostika, Hillerød, Denmark) were used. Manufacturers and stock solutions (5000 mg/L in 121 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Brøndby, Denmark)) were the following: fluconazole 122 
and amphotericin B (Sigma-Aldrich), anidulafungin and voriconazole (Pfizer A/S, Ballerup, 123 
Denmark), micafungin (Astellas Pharma Inc., Tokyo, Japan) and isavuconazole (Basilea, 124 
Pharmaceutica Ltd., Basel, Switzerland). C. parapsilosis ATCC22019 and/or C. krusei ATCC6258 125 
were included as quality controls in each run (34). Susceptibility classification was performed 126 
according to established or proposed EUCAST breakpoints and ECOFFs (Supplementary table 1) 127 
(35–38). Finally, amphotericin B: ≤1 mg/L: S and fluconazole: ≤2 mg/L: S was used for remaining 128 
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species to illustrate the overall susceptibility of those species or groups of fungi but should not be 129 
interpreted as an exact figure of clinical susceptibility or resistance.  130 
Molecular identification and FKS gene sequence analysis (for selected isolates) 131 
Sequencing of internal transcribed spacer regions ITS1 and ITS2 (ITS) (18) and translation 132 
elongation factor (TEF, for Fusarium) was performed as previously described (39). Echinocandin 133 
target hot-spots in FKS1, and for C. glabrata also FKS2, DNA sequence analysis was performed for 134 
resistant isolates and sequences compared to relevant reference sequences including Genbank 135 
accession no. JX899422 for C. kefyr (40).  136 
Consumption of antifungal compounds 137 
Information concerning overall use of antifungal agents in Denmark 2000–15 was retrieved from 138 
the Danish Medicines Agency (at www.medstat.dk). Posaconazole tablet and iv formulation were 139 
marketed in Denmark in 2014. The licensed maintenance dose of these formulations is 300 140 
mg/day compared to 800 mg/day for the oral suspension. To reflect the actual number of 141 
individual dosages given in 2014-15, a corrected use was calculated (0.3 g enterotablet or iv 142 
infusion and 0.8 g oral solution translated to 1 DDD). The antifungal use (DDD/1000 143 
inhabitants/year) from Norway, Sweden and Finland was retrieved from 144 
www.legemiddelforbruk.no, www.socialstyrelsen.se, and www.fimea.fi. Posaconazole formulation 145 
information was not available and unadjusted posaconazole DDDs were used for comparison 146 
between the Nordic countries and Denmark.  147 
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Statistics  148 
Chi-square test or Fisher’s exact test was used for comparison of proportions and the Chi-square 149 
test for trend used for evaluation of changes in species distribution over the 12-year surveillance 150 
period. Calculations were performed using GraphPad Prism Version 6.04 (GraphPad Software Inc., 151 
La Jolla, CA, USA). For twelve episodes (10 in 2004 and one each in 2005 and 2007) the gender was 152 
unknown. When possible, episodes were allotted evenly to genders in specific 10-year age groups, 153 
but in four instances single cases within age groups were excluded from analysis of gender- and 154 
age-specific incidence rates, conducted with linear Poisson regression/incidence ratio rate 155 
calculation (package: epitools). P-values <0.05 (two-tailed) were considered statistically significant. 156 
Binomial univariate logistic regression was used to investigate associations between species 157 
distribution and year, age, gender and BC system using R (R Foundation for Statistical Computing, 158 
Vienna, Austria. URL https://www.R-project.org/). For this analysis and to assure independence of 159 
observations only incident cases were included. Covariates with a p<0.1 were investigated further 160 
in a binomial multivariate analysis. Year, age, gender, and BC system were all retained in the 161 
multivariate analysis and independent significant findings displayed. The p-value also calculated 162 
when excluding the main tertiary referral hospital serviced by centre 1-RH.163 
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RESULTS 164 
Current epidemiology (2012-2015) in a 12-year perspective 165 
A total of 1939 isolates from 1883 unique episodes and 1813 patients were included in the period 166 
2012-15. The mean and median age of patients were 65 years (range: 0-98 years) and 69 years 167 
(interquartile range 58-77 years), respectively. Overall, 59.7% of patients were males and the 168 
proportion increased (p=0.002) (Table 1). In a 12-year perspective, both the age of candidaemia 169 
patients and the male proportion increased (Table 2). 170 
The average episode rate was 8.38/100,000 inhabitants (range 7.6-9.1) in 2012-15 and overall 171 
stable over twelve year although a significant increase in incidence was evident from 2004-11 172 
(p=0.001). The population grew with 4.9% from 2004-15, the number of discharges increased by 173 
20.2%, but the number of bed days decreased by 18.5% (2005-15). Consequently, the incidence 174 
rate/1,000 admissions declined whereas the incidence rate/10,000 bed days increased (Table 2). 175 
The incidence varied across centres in 2012-15, from 3.1-13.1/100,000 inhabitants, 0.2-0.7/1000 176 
discharges and 0.6-1.8/10,000 somatic bed days (Supplementary table 2). 177 
The highest incidence was seen at the extremes of age, i.e. 9.5/100,000 in the <1-year old and 178 
17.2, 31.4, 39.9 and 21.2 per 100,000 inhabitants in the 60-69, 70-79, 80-89, and 90+ years old age 179 
groups, respectively, in 2012-15. Moreover, the incidence was significantly higher in males 180 
compared to females (10.0 vs 6.8, IRR 1.5; 95% CI (1.3-1.6)) (Figure 1). In the 12-y perspective, 181 
decreasing age-specific incidence rates were observed in all age groups >50 years of age except 182 
>80 years (Figure 1). Whereas the overall female incidence rate numerically decreased over the 183 
three 4-year periods (p=0.05), the male incidence remained stable and with a significant increase 184 
between 80-89 years (Figure 1).  185 
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C. albicans accounted for the majority of isolates (47.9%) in 2012-15, followed by C. glabrata 186 
(31.8%). C. tropicalis, C. krusei, C. dubliniensis and C. parapsilosis each accounted for <4.3%. Sixty-187 
nine (3.6%) of the isolates belonged to other Candida species, thirty-two (1.7%) to other fungal 188 
genera whereof eleven were mould and another eleven Saccharomyces cerevisiae isolates (Table 189 
1). Poly-fungal episodes (n=53) involved 5.6% of isolates. Over the twelve years, the proportion of 190 
C. albicans decreased (p<0.0001) whereas the proportion of C. glabrata increased (p<0.0001) 191 
(Figure 3). This development was still observed despite conservatively assigning non-C. albicans as 192 
C. glabrata among isolates from 2004-09. The proportion of C. dubliniensis increased significantly 193 
from 2.3% to 3.6% (p=0.01) whereas no change was detected for other species (Figure 3). The 194 
increase in C. glabrata was significant for age groups 1-9, 30-39, 50-59, and 70-79 again despite 195 
assigning early isolates identified as only non-albicans to be C. glabrata (p<0.03 for all groups; 196 
Figure 2).  197 
The species distribution in 2012-15 varied by age, gender, and by centre (Supplementary table 2 198 
and 3). Correlation between species and age, gender, BC system, and calendar year was 199 
investigated for all incident cases (only first episode included in the full 12-year period) in a 200 
univariate and multivariate logistic regression analysis (Table 3). A decrease in C. albicans and an 201 
increase in C. glabrata and C. dubliniensis episodes over time was found. C. glabrata was positively 202 
associated with female sex whereas the opposite was the case for C. tropicalis. C. albicans, C. 203 
parapsilosis, C. dubliniensis, and “other fungi” were associated with younger patients whereas the 204 
odds of being infected with C. glabrata increased with age. Candidaemia involving C. glabrata was 205 
positively associated with BACT/ALERT whereas the opposite was true for C. parapsilosis, C. krusei, 206 
and “other fungi” (multivariate analysis). For “other fungi” this association disappeared when 207 
excluding centre 1-RH.  208 
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Susceptibility  209 
For the six most common Candida species susceptibility patterns were largely as predicted by the 210 
species identification (Table 4). However, acquired resistance in Candida was occasionally 211 
detected and is detailed below per drug class.  212 
Azoles: Overall, significantly fewer 1147/1892 (60.6%) of the isolates were fluconazole susceptible 213 
in 2012-15 compared to 1137/1745 (65.2%) in 2008-11 and 972/1420 (68.5%) in 2004-7, 214 
respectively (trend test p<0.0001). Among C. albicans, C. dubliniensis, C. parapsilosis and C. 215 
tropicalis, 2.1% (24/1128) were non-wild-type (wt) for fluconazole and 1.4% (16/1128) resistant 216 
(0.4% C. albicans, 4.2% C. dubliniensis, 6.5% C. parapsilosis, and 6.2% C. tropicalis) (Table 4). Two 217 
of four fluconazole-resistant C. parapsilosis isolates were voriconazole resistant. Six of seven 218 
fluconazole non-susceptible C. tropicalis isolates had a trailing phenotype making MIC 219 
determination difficult due to a 50% growth inhibition over a broad range of MIC values (which 220 
was also the case for voriconazole and isavuconazole). Altogether fourteen isolates (1.2%) of the 221 
four species were voriconazole resistant/non-wt and ten (0.9%) were isavuconazole non-wt, none 222 
of which were fluconazole susceptible.  223 
For C. glabrata a bimodal fluconazole MIC distribution was observed, with the peaks at MIC values 224 
of 4 mg/L and 64 mg/L; 9.1% were resistant (MIC>32 mg/L). This proportion declined from 2012-225 
13 to 2014-15 (11.4 % vs 6.6%, p=0.04). Finally, 8.1% of C. glabrata were also non-wt for 226 
voriconazole and 1.4% of C. krusei were non-wt for voriconazole. 227 
 228 
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Echinocandins: Acquired echinocandin resistance increased compared to the previous years: 229 
29/1754 (1.7%) compared to 10/1581 (0.6%) and 0/1294 (0%), in 2008-11 and 2004-7, respectively 230 
(p<0.001).   231 
The twenty-nine Candida isolates displaying acquired anidulafungin resistance in 2012-15 232 
consisted of 4.2% of C. dubliniensis, 2.7% C. glabrata, 6.8% C. krusei, 2.5% C. tropicalis, and 23% 233 
(3/13 isolates) C. kefyr isolates (Table 4). FKS sequencing detected hot spot alterations in 13/16 C. 234 
glabrata, 1/5 C. krusei (with the remaining four having L701M outside the hotspot which has not 235 
been found uniformly associated with echinocandin resistance in our laboratory), 0/3 C. 236 
dubliniensis, 2/2 C. tropicalis, and 1/3 C. kefyr. Five of the 16 (31%) C. glabrata isolates were 237 
fluconazole cross-resistant and thus multidrug resistant. For less common species see 238 
supplementary data 4. 239 
 240 
Amphotericin B: Acquired amphotericin B resistance was found in 1.3% of fungaemia isolates and 241 
1.0% (18/1851) of Candida isolates in 2012-15 (Table 4) including 1.5% C. glabrata isolates, 8.2% C. 242 
krusei isolates, two C. nivariensis, and one C. norvegensis isolates. In all instances, the MIC was 2 243 
mg/L and thus one dilution step above the breakpoint.  244 
 245 
Antifungal consumption  246 
The antifungal consumption in Denmark has increased over the first 10 years of observation but 247 
stabilised or decreased during the last 2-3 years except for posaconazole (17, 18) (Figure 4). Most 248 
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fluconazole, ketoconazole, itraconazole, and terbinafine was used in the primary health care 249 
sector 2004-15 (69.9%, 87.9%, 94.7% and 99.8%, respectively).  250 
Denmark had a higher consumption of systemic antifungal drugs per 1,000 inhabitants compared 251 
to the other Nordic countries (2015: total 790 DDDs (DK) vs 512, 321, and 762 DDDs (Norway, 252 
Sweden and Finland)) and especially of the azoles (+44-174%; 237 DDDs (DK) vs 87, 111, and 164 253 
DDDs (Norway, Sweden, and Finland, respectively)) despite a continued annual increase in 254 
fluconazole consumption until 2012 (Finland) or 2015 (Norway and Sweden). Caspofungin was the 255 
main echinocandin used. Anidulafungin was introduced in 2009 and accounted for 6-13% of the 256 
echinocandin use until 2013 and 25% in 2015. 257 
258 
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DISCUSSION 259 
The Danish fungaemia incidence rate declined slightly in 2012-15 after an increase in the 260 
preceding 8 years. Whether this is just annual variations or an actual declining incidence is not yet 261 
known. In the other Nordic countries and Scotland incidence rates have been increasing during the 262 
1990s/the early 2000s, but for most parts appear now to have stabilized around a lower level 263 
compared to Denmark (7–11, 13–16, 41) (Supplementary Figure 1). Outliers are Australia with a 264 
low incidence but modest increase, and metropolitan Spain with a notable increase to 8.1/100,000 265 
partly driven by a doubling of the incidence among children <1 year old (3, 12). A study of US 266 
community hospital discharge records of invasive candidiasis of >1 month olds also demonstrated 267 
a minor decrease from 2005-12 for both genders (42). This finding was corroborated by a 268 
population based study from two metropolitan areas in the USA where their unprecedented high 269 
incidence rates declined from 2008-13 (Atlanta 14.1 to 9.5 and Baltimore 30.9 to 14.4). This 270 
change was found in almost all age groups but limited to patients with central venous catheters 271 
(85%) and was hypothesized to be related to the introduction of an infection control bundle 272 
focusing on i.v. catheter management (43). 273 
A recent study has examined the observed differences in incidence rates from 2010-11 between 274 
the Nordic countries. Denmark had a higher prevalence of malignant haematological disease 275 
compared to the other Nordic countries, but no demographic differences could justify the higher 276 
rate. Despite a similar overall antibacterial consumption (DDDs/1000 inhabitants/day), the use of 277 
penicillin, piperacillin-tazobactam, metronidazole, carbapenem, and colistin was significantly 278 
higher in Denmark (16). Metronidazole and broad-spectrum beta-lactams are associated with 279 
profound impact on the GI flora thereby potentially selecting for yeast (44, 45). Moreover, a 280 
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higher use of broad-spectrum antibiotics and the increasing utilisation of BC reported in Denmark 281 
(particularly in the ≥ 65 years old population) may be markers of Danish patients being more 282 
severely ill or the introduction of sepsis packages (including timely diagnostics) (46).  283 
Despite the high overall incidence, a more diverse picture was observed among children and the 284 
elderly. The incidence rate has remained constant in the <1-year old (10.8/100.000 population) in 285 
the 12-year perspective and was comparable to rates reported from Norway, Finland, and England 286 
and Wales (6.6-11/100.000) (8, 15, 47) but low in a global perspective (20 to >90/100,000) (3, 6, 287 
14, 48, 49). Such differences suggest that socioeconomic factors and infection control practises 288 
may play an important role as also suggested in the study from Atlanta and Baltimore (43). In 289 
contrast, the incidence rate in the elderly population was higher than in any population based 290 
study in Caucasians ((3, 6, 8, 14, 15, 48, 49) and only exceeded by the rate from the mixed 291 
population in Atlanta and Baltimore (43). The high Danish rates in the elderly were mainly driven 292 
by a significantly higher and increasing rate in males aged 80-89 years. The reason for this is 293 
unclear. Colon cancer and haematological malignancies are recognised risk factor for candidaemia. 294 
Both malignancies are more common in males increasing with advancing age and the total 295 
prevalence of gastro-intestinal tract (incl. pancreas and liver) cancers as well as large groups of 296 
haematological disease (leukaemia and non-Hodgkin lymphoma) have increased more in males 297 
during the last decade 2004-14 (http://www.ancr.nu).  298 
The previously observed species-shift towards non-albicans species and particularly C. glabrata 299 
continued 2012-15. This trend has been observed in several population-based candidaemia 300 
surveys (3, 12, 13, 20, 50). The increase in the proportion of C. glabrata has happened 301 
concomitantly with an increase in azole use in Denmark and with the population getting older. 302 
 o
n
 D
ecem
ber 20, 2017 by SYDDANSK UNIVERSITETSBIBLIO
TEK
http://jcm.asm.org/
D
ow
nloaded from
 
18 
 
Sweden, Norway, Finland, and Iceland have not witnessed the same increase in the proportion of 303 
C. glabrata during the last decade of surveillance although sharing demographic characteristics. 304 
Despite an increase in systemic azole use in all four countries, the overall use was substantially 305 
lower in the other Nordic countries (Figure 4, (14)). In 2015, the overall systemic azole 306 
consumption in Norway was comparable to the fluconazole use alone in Denmark in 2004. In 307 
contrast, the use of topical azoles for vaginitis was twice as high in Norway compared to Denmark 308 
(an average of 375 vs 213 DDD/1000 inhab./year). We speculate whether this increasing selection 309 
pressure mediated by systemic azoles over the twelve-year period has facilitated the increasing 310 
proportion of C. glabrata in the Danish setting. 311 
The age-dependent species distribution of C. parapsilosis and C. glabrata and the influence of 312 
blood culture system on the detection of C. glabrata were confirmed in a multivariate analysis (15, 313 
17, 18, 51). Although the gradual change from BACTEC to BACT/ALERT may have contributed to 314 
the increase in C. glabrata no centres have changed to BACT/ALERT since January 2011. Less 315 
importance has been placed on the impact of gender in relation to C. glabrata. C. glabrata was 316 
correlated to the female sex and was especially common above the age of 40 years, an 317 
observation also made in our previous study but to our knowledge not reported elsewhere (18). 318 
One reason for this could be the gender-inequality in the antifungal consumption in the primary 319 
health care sector. Prior fluconazole use has been shown to be associated with emergence of C. 320 
glabrata (18, 22, 52, 53). Fluconazole is the main azole used in Denmark, and the majority is 321 
administered in the primary sector. In this setting (2012-15), 2/3 of the sale of fluconazole was 322 
prescribed for the age groups 20-65 years and with a 4.8 female/male ratio of DDDs/1000 323 
inhabitants/day. Genotyping studies have confirmed that the infecting organism derives from the 324 
colonizing flora (54). We therefore hypothesize that the considerable use of fluconazole in adult 325 
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females in the primary health care sector may play a role in the over-representation of C. glabrata 326 
in adult females. Consequently, the recommended use of topical azoles rather than systemic 327 
treatment whenever possible has been reinforced in the 2012 national guidelines (55). We did not 328 
see an increase in C. krusei. Although inherently resistant to fluconazole and potentially selected 329 
for by azole treatment, this species is also less pathogenic (56). No nationwide study has, to our 330 
knowledge, reported an increase in C. krusei proportions reflecting that infections occur primarily 331 
in a well-defined subset of patients most of whom are already recipients of prophylaxis.  332 
Fluconazole non-susceptibility was detected in more than one third of isolates, mainly driven by an 333 
increase in C. glabrata. Of note, 9.1% of C. glabrata isolates were fluconazole and voriconazole 334 
cross-resistant and unlikely to respond to even high dosages of azoles. Non-susceptibility to 335 
fluconazole in C. tropicalis (8.6%) was primarily caused by heavy trailing growth and affected all 336 
azoles equally, impeding precise and reproducible MIC determination. Less than 50% trailing is 337 
commonly observed in C. tropicalis and was not associated with differential clinical efficacy of 338 
fluconazole in 21 C. tropicalis cases included in multivariate analysis. The overall mortality for 339 
these patients was less than 10% suggesting the majority were not severely ill (57, 58). Therefore, 340 
it still remains to be elucidated if isolates displaying heavy trailing are indeed good targets for 341 
fluconazole treatment particularly in the setting of severe disease.   342 
Acquired echinocandin resistance remained low but increased. All isolates with an MIC elevated 343 
≥2 dilution step above the breakpoint had an FKS hot spot mutation whereas this was only the 344 
case in 4/16 isolates with an MIC one dilution step above the breakpoint. The majority of isolates 345 
with hot spot mutations were C. glabrata and 31% were fluconazole cross-resistant as reported 346 
elsewhere (31, 59, 60). Studies from the USA has demonstrated increasing echinocandin resistance 347 
rates in C. glabrata (60, 61). In this context, it is worrying that we now see emerging resistance in 348 
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2.7% of our C. glabrata, particularly when no isolates were found in 2004-7 and only 1.4% during 349 
2008-12. Furthermore, we are now seeing 2.5% confirmed resistance in C. tropicalis and FKS 350 
mutations in C. krusei and C. kefyr. Echinocandin resistance has been associated with prior therapy 351 
and in C. glabrata particularly with the presence of mutations in the DNA mismatch repair gene 352 
MSH2 (62). The emergence of echinocandin resistance in Denmark follows a significant increase in 353 
echinocandin consumption from 2004-15. These observations suggest that longer term 354 
echinocandin should be minimized if possible including when used empirically (63, 64). 355 
In contrast to the increasing resistance observed for azoles and echinocandins, 98% of all isolates 356 
were amphotericin B susceptible which is in agreement with previous reports showing broad 357 
activity and no indication of acquired resistance (18).   358 
 359 
In conclusion, Denmark remains a high incidence country for fungaemia where less than two thirds 360 
of isolates are now fully fluconazole susceptible and where acquired echinocandin resistance is on 361 
the increase. Continued epidemiological surveillance is important and efforts should be directed 362 
towards improved diagnostics and lowering the antifungal selection pressure including regulation 363 
of the fluconazole use in the primary health care sector. 364 
 365 
Preliminary data has been presented as a short oral poster at the 27th ECCMID in Vienna 2017. 366 
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FIGURE AND TABLE LEGENDS 621 
Figure 1: Age- and gender-specific incidence rates per 100,000 population by three 4-year intervals 622 
(2004-2015). 623 
 624 
The overall male incidence rate was stable whereas the female declined numerically. Males had a 625 
slight decrease for the age 50-59 (p 0.04) and a significant increase for the age group 80-89 (p 626 
<0.0001). Females had significant decreases in age groups 40-49 and 60-69 (and only an increase 627 
in the low incidence age group 20-29 years).  628 
 629 
Figure 2: Species distribution of blood stream infections on age groups 2012-2015. 630 
 631 
Figure 3: Species distribution (isolates in %) over three 4-year periods during 2004-2015. 632 
 633 
The presented percentages are based on isolate numbers during the 4-year periods. Significant p 634 
values from a Chi-square test for trend is presented. (for C. dublinensis a p value of 0.01 was found 635 
due to an increase in isolates 2014-2015). 636 
 637 
Figure 4: Annual consumption of systemic antifungal compounds in DDDs/1000 inhabitants in 638 
2004-2015. Hospital use is shown in orange and use in the primary healthcare sector in red. The 639 
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total annual consumption in Norway, Sweden and Finland is inserted for comparison (dark grey, 640 
light grey and white bars, respectively) 641 
 642 
1The DDD for caspofungin is 50 mg whereas the DDDs for micafungin and anidulafungin are 0.1g. 643 
2 2 For posaconazole, an enterotablet and an iv formulation was introduced on the Danish market 644 
in 2014. The licensed daily dose of these new formulations is 300 mg/day (after a loading dose) 645 
whereas the treatment dose of the suspension is 800 mg/day. The official defined DDDs was for all 646 
three formulations 0.8 g (recently in 2017 changed to 0.3 g). We have translated DDDs to reflect 647 
the actual use (enterotablets and iv formulation: 1 DDD of 0.3 g (red/white stripes) and oral 648 
suspension: 1 DDD 0.8 g (solid red)). Total use in the Nordic countries and DK (uncorrected; grey 649 
line) is for a DDD of 0.8 g. 650 
 651 
Table 1: Characteristics of the national fungaemia surveillance scheme on incidence rates, age, 652 
gender, and species distribution 2012-2015 653 
 654 
a) Candida spp. includes: C. lusitaniae (19); C. kefyr (13); C. fermentati (8); C. pelliculosa (6); C. 655 
guilliiermondii (5); C. inconspicua (4); C. orthopsilosis (3); C. magnoliae and C. nivariensis (2 each); 656 
C. fabianii, C. metapsilosis, C. norvegensis, C. palmioleophila and C.utilis (1 each) and finally two 657 
Candida isolates not referred for species identification. 658 
b) Other fungi include: S. cerevisiae (11); Fusarium dimerum and Cryptococcus neoformans (4 659 
each); Fusarium solani (3); Fusarium oxysporum, Rhodutorula mucilaginosa and Saprochaeta 660 
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clavata (2 each); A. fumigatus, Penicillium marneffei, Trichosporon asahii and Williopsis saturnus (1 661 
each). 662 
 663 
Table 2: Number of isolates, demographics of patients, and blood culture system use during three 664 
4-year periods 2012-2015 665 
 666 
For information of isolates included please see table 1 (2012-2015) and refer to references (17, 18) 667 
ND: not determined. For the statistical analyses Chi-square trend test was used apart from age and 668 
episodes rates where a linear logistic regression analysis was employed. 669 
a) Number of bed days 2004 were not available and the figure from 2005 was used for 2004. 670 
 671 
Table 3: Binomial logistic regression analysis of variables associated with changing species 672 
distribution in Denmark 2004-15. Only incident cases were included, and only significant findings 673 
displayed. For the multivariate analysis year, age, gender, and BC system were all kept in the 674 
model. 675 
 
676 
a 95% confidence intervals. Due to an interaction between calendar year and BC system, the year 677 
factor is split on 1BACT/ALERT (top) and 2BACTEC (bottom).b p value when excluding the main 678 
tertiary hospital Rigshospitalet (Centre 1-RH). 679 
 680 
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Table 4: Susceptibility pattern of Danish fungaemia isolates collected in 2012-15 to six antifungal 681 
compounds. The EUCAST breakpoints and ECOFFs (Supplementary table 1) are used for the 682 
classification as susceptible (S), resistant (R), and non-wildtype (non-wt). 683 
 684 
S: susceptible; R: resistant; non-wt: non-wildtype (as the MIC was above the ECOFF). 685 
Empty cells indicate that there were no isolates for which the MIC had the indicated value.  686 
- The indicated concentration of that particular drug was not tested 687 
Bold numbers indicate isolates for which the MIC were above the ECOFF and with underlined 688 
numbers indicating isolates that were resistant.  689 
EUCAST breakpoints and ECOFFS were used. For Candida species and “other fungi” an 690 
amphotericin B breakpoint of 1 mg/L was used. For “other fungi” a fluconazole breakpoint of 2 691 
mg/L was used. These last cut-offs are only an indication of the susceptibility profile for the given 692 
species/group of isolates (and a conservative estimate of the proportion of cases that are likely 693 
good targets for the compound in question). 694 
1 For the echinocandins and fluconazole 29 and 23 isolates were tested, respectively. 2 For the 695 
echinocandins and fluconazole, 1898 and 1892 isolates were tested, respectively. 696 
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Table 1: Characteristics of the national fungaemia surveillance scheme on incidence rates, age, gender, and species distribution 2012-2015. 
 2012 2013 2014 2015  2012-2015 
Number of Isolates 492 523 441 483  1939 
Number of Episodes 479 508 429 467  1883 
Number of Patients 461 490 419 443  1813 
Mean patient age (95% CI) 66.1 (64.5;67.7) 64.7 (63.2;66.3) 64.8 (63.1; 66.5) 65.7 (63.1; 66.5)  65.3 (64.5; 66.2) 
Median patient age (interquartile range) 69 (58; 78) 68 (59; 77) 69 (58; 77) 69 (59; 77)  69 (58; 77) 
Gender % male 55.1% 56.8% 63.5% 64.0%  59.7% 
Episode rate       
/100,000 inhabitants 8.58 9.07 7.62 8.25  8.38 
/1000 discharges 0.35 0.37 0.31 0.34  0.34 
/10,000 bed days 1.05 1.14 0.97 1.008  1.06 
Isolates on species (%)      
C. albicans 230 (47%) 268 (51%) 225 (51%) 205 (42%)  928 (47.9%) 
C. dubliniensis 13 (3%) 12 (2%) 20 (5%) 26 (5%)  71 (3.7%) 
C. glabrata 170 (35%) 155 (30%) 125 (28%) 167 (35%)  617 (31.8%) 
C. krusei 19 (4%) 19 (4%) 20 (5%) 17 (4%)  75 (3.9%) 
C. parapsilosis 16 (3%) 18 (3%) 10 (2%) 20 (4%)  64 (3.3%) 
C. tropicalis 18 (4%) 23 (4%) 15 (3%) 27 (6%)  83 (4.3%) 
Candida species
a
 18 (4%) 19 (4%) 17 (4%) 15 (3%)  69 (3.6%) 
Other fungi
b
 8 (2%) 9 (2%) 9 (2%) 6 (1%)  32 (1.7%) 
a) Candida spp. includes: C. lusitaniae (19); C. kefyr (13); C. fermentati (8); C. pelliculosa (6); C. guilliiermondii (5); C. inconspicua (4); C. orthopsilosis (3); C. magnoliae and C. nivariensis (2 each); C. fabianii, C. 
metapsilosis, C. norvegensis, C. palmioleophila and C.utilis (1 each) and finally two Candida isolates not referred for species identification. 
b) Other fungi include: S. cerevisiae (11); Fusarium dimerum and Cryptococcus neoformans (4 each); Fusarium solani (3); Fusarium oxysporum, Rhodutorula mucilaginosa and Saprochaeta clavata (2 each); A. 
fumigatus, Penicillium marneffei, Trichosporon asahii and Williopsis saturnus (1 each). 
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Table 2: Number of isolates, demographics of patients, and blood culture system use during three 4-year periods 2012-2015. 
 
2004-7 2008-11 2012-15  
Time trend 
(p value) 
Isolates 1932 2049 1939   
Episodes 1874 1994 1883   
Patients 1795 1895 1813   
Mean age (95% CI) 61.9 (60.2; 63.6) 63.0 (61.3; 64.7) 65.3 (64.5; 66.2)  0.0002 
Median age (25% quartiles) 65 (54; 75) 66 (56; 74) 69 (58; 77)  ND 
Male gender (%) 56.4 59.2 59.7  0.01 
Episode rate      
/100,000 inhabitants 8.64 9.03 8.38  0.34 
/1000 discharges 0.39 0.38 0.34  <0.0001 
/10,000 bed days 0.90
a 
1.03 1.06  <0.0001 
Proportion of isolates from BACTEC 
(%) 
45.0 36.2 22.0  <0.0001 
For information of isolates included please see table 1 (2012-2015) and refer to references (17, 18). 
ND: not determined. For the statistical analyses Chi-square trend test was used apart from age and episodes rates where a linear logistic regression analysis was employed. 
a) Number of bed days 2004 were not available and the figure from 2005 was used for 2004. 
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Table 3: Binomial logistic regression analysis of variables associated with changing species distribution in Denmark 2004-15. Only incident cases were 
included, and only significant findings displayed. For the multivariate analysis year, age, gender, and BC system were all kept in the model.  
Species (no.) Univariate  Multivariate 
 Odds ratio 95% CI
a
 p p
b
  Odds ratio 95% CI
a
 p p
b
 
C. albicans (2967)          
Calendar year (Year) 0.94 0.93-0.96 <0.001 <0.001  0.95
1 
0.94-0.97 <0.001 <0.001 
      0.92
2
 0.89-0.94 <0.001 <0.001 
Age (Year) 0.995 0.992-0.998 <0.001 0.001  0.995 0.992-0.998 0.002 0.002 
          
C. glabrata (1369).          
Calendar year (Year) 1.08 1.06-1.10 <0.001 <0.001  1.06 1.04-1.08 <0.001 <0.001 
      1.11 1.07-1.15 <0.001 <0.001 
Blood culture system (BACTEC) 0.65 0.57-0.75 <0.001 <0.001  0.78 0.68-0.90 <0.001 0.004 
Gender (Female) 1.15 1.01-1.30 0.032 0.023  1.17 1.03-1.33 0.014 0.009 
Age (Year) 1.02 1.02-1.03 <0.001 <0.001  1.02 1.02-1.02 <0.001 <0.001 
          
C. tropicalis (237)          
Gender (Female) 0.74 0.56-0.97 0.034 0.018  0.74 0.56-0.97 0.033 0.018 
          
C. parapsilosis (171)          
BC system (BACTEC) 1.87 1.38-2.54 <0.001 0.005  1.70 1.24-2.34 0.001 0.045 
Age (Year) 0.98 0.98-0.99 <0.001 <0.001  0.98 0.98-0.99 <0.001 <0.001 
          
C. krusei (219)          
BC system (BACTEC) 2.00 1.52-2.62 <0.001 <0.001  2.07 1.56-2.74 <0.001 <0.001 
          
C. dubliniensis (149)          
Calendar year (Year) 1.06 1.01-1.12 0.014 0.010  1.07 1.02-1.13 0.007 0.001 
Age (Year) 0.99 0.982-0.997 0.007 0.009  0.989 0.981-0.997 0.008 0.005 
          
Other fungi (83)          
BC system (BACTEC) 1.87 1.21-2.89 0.005 0.046  1.71 1.09-2.69 0.019 0.10 
Age (Year) 0.98 0.97-0.99 <0.001 <0.001  0.98 0.97-0.99 <0.001 0.001 
a
 95% confidence intervals. Due to an interaction between calendar year and BC system, the year factor is split on 
1
BACT/ALERT (top) and 
2
BACTEC (bottom).
b 
p value when 
excluding the main tertiary hospital Rigshospitalet (Centre 1-RH). 
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Table 4: Susceptibility pattern of Danish fungaemia isolates collected in 2012-15 to six antifungal compounds. The EUCAST breakpoints and ECOFFs 
(Supplementary table 1) are used for the classification as susceptible (S), resistant (R), and non-wildtype (non-wt). 
  No. of isolates with the given MIC (mg/L)  S R non-wt 
 <0.008 0.015 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 32 64 128  No % No %  No % 
C. albicans (914) 
               
 
  
     
Amphotericin B - 
 
4 67 155 356 331 1  - - - - - -  914 100 0 0.0  0 0.0 
Anidulafungin - 874 40       - - - - - -  914 100 0 0.0  0 0.0 
Micafungin 880 29 5       - - - - - -  909 99.5 5 0.5  5 0.5 
Fluconazole - - - - 520 349 34 5 2 
 
1 
 
3 - -  910 99.6 4 0.4  6 0.7 
Voriconazole - - 909 1 1 1     2 - - - -  911 99.7 3 0.3  3 0.3 
Isavuconazole - - 911 
 
1      2 - - - -  ND ND ND ND  3 0.3 
C. dubliniensis (71) 
               
 
  
     
Amphotericin B - 16 18 15 20 2    - - - - - -  71 100 0 0.0  0 0.0 
Anidulafungin - 43 25 3      - - - - - -  68 95.8 3 4.2  3 4.2 
Micafungin 43 24 4       - - - - - -  67 94.4 4 5.6  4 5.6 
Fluconazole - - - - 28 19 13 7 1   2 1 - -  68 95.8 3 4.2  4 5.6 
Voriconazole - - 68 1 
 
1 1     - - - -  69 97.2 2 2.8  2 2.8 
Isavuconazole - - 70  1       - - - -  ND ND ND ND  1 1.4 
C. glabrata (603) 
   
 
           
 
  
     
 Amphotericin B - 1 5 13 86 128 218 143 9 - - - - - -  594 98.5 9 1.5  9 1.5 
Anidulafungin - 129 200 258 6 5 1 2 2 - - - - - -  587 97.3 16 2.7  16 2.7 
Micafungin 434 132 25 3 2 1 3 1 2 - - - - - -  591 98.0 12 2.0  12 2.0 
Fluconazole - - - - 
 
1 1 22 164 278 53 15 14 38 17  0 0.0 55 9.1  55 9.1 
Voriconazole - - 108 248 157 13 10 18 31 17 1 - - - -  IE IE IE IE  49 8.1 
Isavuconazole - - 426 78 20 6 17 24 17 15 0 - - - -  ND ND ND ND  ND ND 
C. krusei (73) 
               
 
  
     
Amphotericin B -    1 4 30 32 6 - - - - - -  67 91.8 6 8.2  6 8.2 
Anidulafungin - 11 16 41 4    1 - - - - - -  68 93.2 5 6.8  5 6.8 
Micafungin    15 46 11   1 - - - - - -  IE IE IE E  1 1.4 
Fluconazole - - - -       1 17 55 - -  0 0.0 73 100  ND ND 
Voriconazole - -   16 40 15 1 1   - - - -  IE IE IE IE  1 1.4 
Isavuconazole - - 21 19 24 7 2     - - - -  ND ND ND ND  ND ND 
C. parapsilosis (62) 
               
 
  
     
Amphotericin B -    6 34 20 2 
 
- - - - - -  62 100.0 0 0.0  0 0.0 
Anidulafungin -     2 7 37 16 - - - - - -  0 0.0 ND ND  ND ND 
Micafungin      1 13 35 13 - - - - - -  0 0.0 ND ND  ND ND 
Fluconazole - - - - 
 
5 31 16 3 3 1 1 2 - -  55 88.7 4 6.5  7 11.3 
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Voriconazole - - 53 5 2   1 1   - - - -  60 96.8 2 3.2  2 3.2 
Isavuconazole - - 61 1        - - - -  ND ND ND ND  1 1.6 
C. tropicalis (81) 
               
 
  
     
Amphotericin B -     26 41 14  - - - - - -  81 100 0 0.0  0 0.0 
Anidulafungin - 33 33 13 1  1   - - - - - -  79 97.5 2 2.5  2 2.5 
Micafungin 23 28 24 5     1 - - - - - -  80 98.8 1 1.2  1 1.2 
Fluconazole - - - - 10 22 26 15 1 2 1 2 2 - -  74 91.4 5 6.2  7 8.6 
Voriconazole - - 66 4 4 3 
 
1 
 
2 1 - - - -  74 91.4 7 8.6  7 8.6 
Isavuconazole - - 76 
 
2     2 1 - - - -  ND ND ND ND  5 6.2 
Candida sp. (65) 
               
 
  
     
Amphotericin B -   6 12 19 19 6 3 - - - - - -  62 95.4 3 4.6  ND ND 
Anidulafungin - 12 9 17 8 2 7 7 3 - - - - - -  ND ND ND ND  ND ND 
Micafungin 2 6 12 23 4 3 9 3 3 - - - - - -  ND ND ND ND  ND ND 
    Fluconazole - 
   
4 11 16 3 6 8 3 6 8 - -  40 61.5 17 26.2  ND ND 
Voriconazole - 
 
35 6 14 3 5 1   1 - - - -  ND ND ND ND  ND ND 
Isavuconazole - 
 
46 6 6 2 1 3   1 - - - -  ND ND ND ND  ND ND 
Other fungi (31)
1 
               
 
  
     
Amphotericin B -   2 4 5 7 7 6 - - - - - -  25 80.6 2 6.5  ND ND 
Anidulafungin -   4 5 2 0 0 18 - - - - - -  ND ND ND ND  ND ND 
Micafungin   1 1 7 2 0 0 18 - - - - - -  ND ND ND ND  ND ND 
Fluconazole - - - -      7 4 5 7 - -  0 0.0 16 69.6  ND ND 
Voriconazole
 - - 
 
4 8 5 2 1 2 7 2 - - - -  ND ND ND ND  ND ND 
Isavuconazole - - 3 7 4 1 3 3 1 1 8 - - - -  ND ND ND ND  ND ND 
Overall
 
(1900)
2 
               
 
  
     
Amphotericin B - 17 27 103 284 574 666 205 24 - - - - - -  1876 98.7 24 1.3  ND ND 
Anidulafungin - 1102 323 336 24 11 16 46 40 - - - - - -  ND ND ND ND  ND ND 
Micafungin 1382 219 71 47 59 18 25 39 38 - - - - - -  ND ND ND ND  ND ND 
Fluconazole - - - - 562 407 121 68 177 298 64 48 147 - -  1147 60.6 177 9.4  ND ND 
Voriconazole - - 1239 269 202 66 33 23 35 26 7 - - - -  ND ND ND ND  ND ND 
Isavuconazole - - 1614 111 58 16 23 30 18 18 12 - - - -  ND ND ND ND  ND ND 
S: susceptible; R: resistant; non-wt: non-wildtype (as the MIC was above the ECOFF). 
Empty cells indicate that there were no isolates for which the MIC had the indicated value.  
- The indicated concentration of that particular drug was not tested 
Bold numbers indicate isolates for which the MIC were above the ECOFF and with underlined numbers indicating isolates that were resistant.  
EUCAST breakpoints and ECOFFS were used. For Candida species and ͞other fungi͟ an amphotericin B breakpoint of 1 mg/L was used. For ͞other fungi͟ a fluconazole 
breakpoint of 2 mg/L was used. These last cut-offs are only an indication of the susceptibility profile for the given species/group of isolates (and a conservative estimate of 
the proportion of cases that are likely good targets for the compound in question). 
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1
 For the echinocandins and fluconazole 29 and 23 isolates were tested, respectively. 
2
 For the echinocandins and fluconazole, 1898 and 1892 isolates were tested, 
respectively. 
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